Gyre Therapeutics Inc Revenue Growth Rates (GYRE), Current and Historic Growth - CSIMarket
CSIMarket
 


Gyre Therapeutics Inc   (NASDAQ: GYRE)
 

GYRE's Revenue Growth by Quarter and Year

Gyre Therapeutics Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GYRE/growth
https://api.csimarket.com/api/v1/companies/GYRE/fundamentals
https://api.csimarket.com/api/v1/companies/GYRE/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
GYRE Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 32.93
2nd Quarter June 29.11
1st Quarter March 22.52
FY 84.56

GYREs Annual Revenue
Gyre Therapeutics Inc 's Revenue in the fiscal year 2025 $ 116.59 millions
Gyre Therapeutics Inc 's Revenue in the fiscal year 2024 $ 105.76 millions
Gyre Therapeutics Inc 's Revenue in the fiscal year 2023 $ 113.45 millions
Gyre Therapeutics Inc 's Revenue in the fiscal year 2022 $ 0.79 millions
Gyre Therapeutics Inc 's Revenue in the fiscal year 2021 $ 7.34 millions




GYRE Revenue third quarter 2026 Y/Y Growth Comment
Gyre Therapeutics Inc reported Revenue growth of 7.77% year on year in the third quarter 2026, to $ 32.93 millions, this is lower than Gyre Therapeutics Inc 's recent average Revenue surge of 106.07%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Revenue growth. While Gyre Therapeutics Inc ' s Revenue increase of 7.77% ranks overall at the positon no. 1896 in the third quarter 2026.




GYRE Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 7.77 %
2nd Quarter June 8.74 %
1st Quarter March 2.09 %
FY   -

Financial Statements
Gyre Therapeutics Inc 's third quarter 2026 Revenue $ 32.93 millions GYRE's Income Statement
Gyre Therapeutics Inc 's third quarter 2025 Revenue $ 30.56 millions Quarterly GYRE's Income Statement


GYRE Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 13.14 %
2nd Quarter June 29.26 %
1st Quarter March -39.46 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #288
Overall #1896

Revenue Y/Y Growth Statistics
High Average Low
3039.92 % 106.07 % -100 %
(Dec 31 2017)   (Dec 31 2021)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #108
Healthcare Sector #288
Overall #1896
Revenue Y/Y Growth Statistics
High Average Low
3039.92 % 106.07 % -100 %
(Dec 31 2017)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Gyre Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
499.32 % 11.71 % -100 %
(Mar 31 2013)  


GYRE's III. Quarter Q/Q Revenue Comment
Gyre Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 13.14%, to $ 32.93 millions, from $29.11 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Gyre Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 367.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #367
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #367
Revenue Q/Q Growth Statistics
High Average Low
499.32 % 11.71 % -100 %
(Mar 31 2013)  


GYRE's III. Quarter Q/Q Revenue Comment
Gyre Therapeutics Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 13.14%, to $ 32.93 millions, from $29.11 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Gyre Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 367.


Gyre Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 119.38
Y / Y Revenue Growth (TTM) 16.83 %
Year on Year Revenue Growth Overall Ranking # 2349
Seqeuential Revenue Change (TTM) 1.99 %
Seq. Revenue Growth (TTM) Overall Ranking # 2413


Cumulative Revenue growth Comment
Although Gyre Therapeutics Inc 's Annual Revenue growth year on year were below company's average 28.63% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 16.83% year on year, from 16.3% in Mar 31 2026.

In the Healthcare sector 339 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1185 to 2349.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 118
Healthcare Sector # 340
Overall # 2349

Revenue TTM Y/Y Growth Statistics
High Average Low
155.14 %
28.63 %
-64.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 118
Sector # 352
S&P 500 # 2413
Cumulative Revenue growth Comment
Although Gyre Therapeutics Inc 's Annual Revenue growth year on year were below company's average 28.63% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 16.83% year on year, from 16.3% in Mar 31 2026.

In the Healthcare sector 339 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1185 to 2349.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 118
Healthcare Sector # 340
Overall # 2349

Revenue TTM Y/Y Growth Statistics
High Average Low
155.14 %
28.63 %
-64.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 118
Sector # 352
S&P 500 # 2413




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GYRE's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Lifeloc Technologies Inc 11.71%$ 11.713 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions
Elanco Animal Health Incorporated11.26%$ 11.258 millions
Koru Medical Systems Inc 11.19%$ 11.194 millions
Elite Pharmaceuticals Inc 11.11%$ 11.113 millions
Pro dex Inc 10.96%$ 10.955 millions
Nrc Health10.95%$ 10.954 millions
Anika Therapeutics Inc 10.91%$ 10.912 millions
Harvard Bioscience Inc 10.86%$ 10.864 millions
Repligen Corp10.86%$ 10.863 millions


About Gyre Therapeutics Inc Revenue Growth Rates (GYRE), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Gyre Therapeutics Inc (CIK 1124105).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-450334
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Gyre Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.